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Background: Post-treatment high-grade gliomas are usually monitored with contrast-enhanced MRI, but 
its diagnostic accuracy is limited as it cannot adequately distinguish between true tumor progression and 
treatment-related changes. According to recent response assessment in neuro-oncology (RANO) 
recommendations PET overcomes this limitation. However, it is currently unknown which tracer yields 
the best results. Therefore, a systematic review and meta-analysis were performed to compare the 
diagnostic accuracy of the different PET tracers in differentiating tumor progression from treatment-
related changes in high-grade glioma patients. 
Method: Pubmed, Web of Science and Embase were searched systematically. Study selection, data 
extraction and quality assessment were performed independently by two authors. Meta-analysis was 
performed using a bivariate random effects model when ≥ 5 studies were included. 
Results: 39 studies (11 tracers) were included in the systematic review. 18F-FDG (12 studies, 171 lesions) 
showed a pooled sensitivity and specificity of 84% (95%CI 72-92) and 84% (69-93), respectively. 18F-
FET (7 studies, 172 lesions) demonstrated a sensitivity of 90% (81-95) and specificity of 85% (71-93). 
11C-MET (8 studies, 151 lesions) sensitivity was 93% (80-98) and specificity was 82% (68-91). The 
number of included studies for the other tracers were too low to combine, but sensitivity and specificity 
ranged between 93-100% and 0-100% for 18F-FLT, 85-100% and 72-100% for 18F-FDOPA and 100% and 
70-88% for 11C-CHO, respectively.  
Conclusions: 18F-FET and 11C-MET, both amino-acid tracers, showed a comparable higher sensitivity 
than 18F-FDG in the differentiation between tumor progression and treatment-related changes in high-
grade glioma patients. The evidence for other tracers is limited, thus 18F-FET and 11C-MET are preferred 
when available. Our results support the incorporation of amino-acid PET tracers for the treatment 
evaluation of high-grade gliomas. 
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  Positron emission tomography (PET) was recently recommended by the response assessment in 
neuro-oncology (RANO) working group in the follow-up during and after treatment of high-grade gliomas 
as conventional magnetic resonance imaging (MRI) is not able to reliably differentiate tumor progression 
from treatment-related changes (1). This differentiation is of utmost importance for making adequate 
treatment decisions and determining prognosis. Contrast enhancement on conventional MRI has been 
classically used to identify tumor progression (2,3). However, treatment effects such as pseudoprogression 
or radiation necrosis occur in about one third of the high-grade glioma patients (4). These treatment effects 
result in blood-brain barrier disruption with similar appearances on post-contrast MRI as tumor 
progression (5–8). This hinders a reliable differentiation of tumor progression from treatment changes.  
PET was thus recently incorporated in the RANO guidelines in addition to MRI as PET adds 
metabolic information regarding tracer accumulation to the anatomical information of MRI. The most 
frequently-used PET tracer, 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG), is glucose-based. However, in 
brain tumors, the use of 18F-FDG is considered to be limited due to the relatively high glucose metabolism 
in normal brain tissue (9). Therefore, the RANO group recommend the use of amino-acid PET for the 
differentiation between treatment-related changes and true tumor progression if PET is used (1). In 
particular, the tracers (S-11C-methyl)-L-methionine (11C-MET), O-(2-18F-fluoroethyl)-L-tyrosine (18F-
FET) and 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine (18F-FDOPA) were suggested to have a higher 
diagnostic accuracy than MRI for this purpose (1).  
Although PET might be beneficial for the differentiation of tumor progression from treatment 
changes in patients with high-grade glioma, until now it is unclear which of the PET tracers can be best 
used to differentiate tumor progression from treatment changes. This systematic review and meta-analysis 
aims to provide this overview of the diagnostic accuracy of all studied PET tracers for distinguishing true 
tumor progression from treatment-related changes in high-grade glioma patients.   





This systematic review and meta-analysis was performed according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis (PRISMA) criteria (10). See electronic Supplementary Table 1 for 
the full PRISMA checklist. Additionally, the AMSTAR 2 guidelines and the Cochrane handbook for 
systematic reviews of diagnostic test accuracy were used (11).  
 
Search Strategy 
We searched PubMed, Embase and Web of Science using a search strategy consisting of database 
keywords and text words, with the latest search on 2018-03-29. The search term was composed to 
describe glioma, PET and treatment evaluation and variations of these words. See electronic 
Supplementary Text 1 for the full search strategy. No filters were used. Studies in English, French and 
German were included. Studies in other languages were excluded. Grey literature was also included in the 
search as Embase contains conference proceedings. 
 
Selection Criteria 
Studies were included if; 
i) they included adult high-grade glioma patients that received first line standard therapy 
according to the Stupp protocol (12) 
ii) patients underwent PET imaging after treatment 
iii) definite diagnosis, either tumor progression or treatment-related changes, was established by 
histological-, imaging-, or clinical follow-up, or a combination of these 
iv) 2x2 tables could be extracted. 
Brain stem or optic gliomas were excluded. Studies were also excluded if their results were not described 
separately for the patient population of interest in our analysis (e.g. if the resulting 2x2 table included 
patients with other tumors than high-grade gliomas, children or patients not treated according to the Stupp 
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protocol). Case reports and studies with <5 eligible patients per PET tracer were also excluded. Studies 
that were conducted before 2005 were excluded as temozolomide, which is known to increase the 
occurrence of treatment-related changes (5,13), was not yet routinely incorporated in standard therapy 
following the Stupp protocol. Studies in which the relevant patient group happened to include exclusively 
patients with tumor progression (and no patients with treatment-related changes) were included in the 
systematic review, but excluded from the meta-analysis as specificity cannot be calculated for these 
studies. 
 
Study Selection, Data Extraction and Quality Assessment 
After duplicates were eliminated, studies were independently screened for eligibility based on title, 
abstract, and subsequently on full text by two authors (P.Z., B.D.). Reference checks have been performed 
for all included articles, as well as for all obtained reviews on the topic of interest.  
Data from the included studies were extracted with the use of a data extraction form. Extracted 
data contained true positives, false positives, true negatives, false negatives, and general characteristics. 
General characteristics included total number of patients, study design, mean age and range, gender, tumor 
histology, used reference standard, and PET characteristics. If multiple methods of examining the PET 
were described that led to different 2x2-tables, then only the method with the highest accuracy was used 
for the forest plots and meta-analysis. However, all methods and 2x2-tables were extracted and provided 
in the results section. Study quality was assessed according to the quality assessment of diagnostic 
accuracy studies (QUADAS-2) (14). 
 
Statistical Analysis 
Sensitivity and specificity with 95% confidence interval (CI) were calculated for all PET tracers in 
RevMan 5.3 (Cochrane collaboration, Copenhagen, Denmark). Visual inspection of the generated forest 
plots was done to assess heterogeneity. We evaluated whether the following factors could explain 
heterogeneity: study type, mean age of patients, WHO type, cut-off value of the index test, and type of 
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follow-up. We performed sub-group analysis (≥5 studies) to explore and explain heterogeneity in test 
characteristics. Moreover, we evaluated whether outliers could be explained by study or patient 
characteristics, and we performed sensitivity analysis without small studies (≤10 patients) to evaluate how 
robust the results are. 
Bivariate random effects models are used, because heterogeneity is to be expected in diagnostic 
test accuracy studies (15). Pooled estimates of sensitivity, specificity, positive likelihood ratios and 
negative likelihood ratios with 95%CI were calculated for each index test consisting of five or more 
studies, using the MIDAS module for meta-analysis of diagnostic test accuracy studies in STATA/SE 12.1 
(College Station, TX, USA). 
To provide insight in the potential clinical consequences, we established a hypothetical cohort of 
100 high-grade glioma patients suggestive of progression for each PET tracer. We calculated 2x2 tables 
by using the mean tumor prevalence (based on the reference standard of the cohort studies included in this 
meta-analysis), pooled sensitivities and specificities of each PET tracer, and we present the number of 
misclassifications, false positives and false negatives.  
  





A total of 2957 unduplicated studies were identified through our electronic database search (Fig. 1 for the 
flow chart). Four of these studies were excluded due to language restrictions. After screening based on 
title and abstract, the 137 remaining studies underwent full-text eligibility assessment, which resulted in 
the identification of 38 relevant studies (see Supplementary Table 2 for an overview of why excluded 
studies were rejected). Reference checks of the included studies yielded one additional study that was 
included (16), thus giving a total inclusion of 39 studies in this systematic review (7,16–53). These studies 
covered a total of 11 different tracers (Supplementary Table 3). Six studies did not include patients with 
treatment-related changes (16,25,36,47,48,52), making them non-eligible for the meta-analysis as 
specificity cannot be calculated. Tracers for which ≥5 studies remained, and thus for which meta-analysis 
was performed, were 18F-FDG (12 studies), 11C-MET (8 studies) and 18F-FET (7 studies). The study 
characteristics of the included studies are shown in Supplementary Table 4. 
The included studies consisted of 771 patients with 832 lesions (either tumor progression or 
treatment-related changes). The mean age of the patients was 50.2 years with 65% being male 
(Supplementary Table 5). The initial lesion was proven to be WHO III in 17.4% (N=145) and WHO IV in 
57.5% (N=478). The remaining 25.1% (N=209) were unspecified WHO III or IV gliomas. Mean tumor 
prevalence was 73.4% (range 33.3-100%). As far as documented in the included studies, histological 
follow-up was used in 30.9% (N=257) of lesions, imaging in 14.4% (N=120) of lesions, clinical follow-up 
in 1.3% (N=11) of lesions, and a combination was used in 26.8% (N=223) of lesions. In 26.6% (N=221) 
of lesions, follow-up was not specified on the individual lesion level. Several of the included studies 
analyzed two PET tracers per lesion (21,29,33–35,41,46,52,53); a total of 951 PETs (see Supplementary 
Table 5 for the tracer distribution) were included. 
 
Methodological Quality of Included Studies 
See Supplementary Text 2 and Supplementary Table 6.  





The forest plots and pooled results are demonstrated in Tables 1 and 2, respectively. The 18F-FDG PET 
forest plot (12 studies, 171 PET scans) shows a substantial variation in both sensitivity and specificity, 
with relatively wide confidence intervals for the specificity in particular. This can be explained by the 
relatively large number of six small studies (19,21,24,33,41,53) (N≤10 patients) for 18F-FDG PET in 
general and a small number of included patients with treatment-related changes in particular. 18F-FDG 
PET showed a pooled sensitivity and specificity of 84% (95%CI 72-92) and 84% (95%CI 69-93), 
respectively. A sensitivity analysis with the exclusion of all small studies with ≤10 patients leads to a 
slightly lower pooled sensitivity and specificity of 82% (95%CI 64-92) and 79% (95%CI 61-90), 
respectively. 
The 18F-FET PET forest plot (10 studies, 207 PET scans) shows more uniformity in the sensitivity 
and specificity between the different studies. Outliers on the low end of sensitivity (47) and of specificity 
(39) can be explained by their low patient numbers. Pooled sensitivity and specificity for 18F-FET PET 
(excluding the three studies that did not include patients without tumor progression (36,47,52) are 90% 
(95%CI 81-95) and 85% (95%CI 71-93), respectively. A sensitivity analysis with the exclusion of one 
small study (39) (N=8) showed a very similar pooled sensitivity and specificity of 90% (95%CI 80-96) 
and 86% (95%CI 72-94), respectively. 
The forest plot for 11C-MET PET (9 studies, 164 PET scans) shows a consistently high sensitivity 
without any major outliers. Two outliers on the low end of specificity (7,30) can again be explained by 
their low number of patients with treatment-related changes and have broad confidence intervals. Pooled 
sensitivity and specificity for 11C-MET PET (excluding one study that did not include patients without 
tumor progression (48) are 93% (95%CI 80-98) and 82% (95%CI 68-91), respectively. A sensitivity 
analysis with the exclusion of the two small studies (21,30) leads to a pooled sensitivity and specificity of 
91% (95%CI 78-97) and 83% (95%CI 68-92), respectively. 
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Eight alternative PET tracers (3′-deoxy-3′-18F-fluorothymidine (18F-FLT), 18F-FDOPA, 11C-
choline (11C-CHO), 18F-fluorocholine (18F-FCH), 13N-ammonia (13N-NH3), modified 11C-MET, α-11C-
methyl-L-tryptophan (11C-AMT) and 18F-FPPRGD2; see Supplementary Table 3 for an overview of the 
included PET tracers and their abbreviations) have been studied for their ability to differentiate high-grade 
glioma tumor progression from treatment-related changes. They have, however, insufficient independent 
reports to be taken into account in the pooled meta-analysis. Individual study data is, however, shown in 
Table 1.  
Particularly noteworthy are 18F-FLT and 18F-FDOPA, the most thoroughly-studied alternative 
tracers. 18F-FLT (five studies, 59 PET scans) has a sensitivity range of 93-100% and a specificity range of 
0-100%, the latter due to the low number of included patients with treatment-related changes and thus 
broad confidence intervals. 18F-FDOPA (four studies, 217 PET scans) has a sensitivity range of 85-100% 
and a specificity range of 72-100%. 
Of the other included tracers, 11C-CHO (two studies, 28 PET scans) has a sensitivity of 100% in 
both studies and a specificity range of 70-88%. 18F-FCH (two studies, 20 PET scans) has a sensitivity of 
100% in both studies and a specificity of 100% in the one study in which it could be determined. 13N-NH3 
(one study, 18 PET scans) showed a sensitivity of 78% and a specificity of 67%. Modified 11C-MET (one 
study, 49 PET scans) showed a sensitivity of 79% and a specificity of 94%. 11C-AMT (one study, 10 PET 
scans) showed a sensitivity and specificity of 100%, as did 18F-FPPRGD2 (one study, 8 PET scans). 
Study type, mean age, WHO type, cut-off value of the index test and follow-up method 
(Supplementary Table 4) were evaluated as covariates but were unable to explain differences in sensitivity 
and specificity for all the studies and PET tracers.  
To provide insight into the clinical implication of these results, the missed number of patients with 
true progression and total number of misclassifications in a hypothetical cohort of 100 high-grade glioma 
patients was calculated for each PET tracer included in the meta-analysis. The average tumor prevalence 
of 73% (found in this systematic review) and the pooled sensitivity and specificity of each PET tracer 
were used in this analysis. With 18F-FDG PET, 12 cases of tumor progression would be missed. For 18F-
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FET and 11C-MET, this would be 7 and 5 missed tumors, respectively. 18F-FDG PET would show a total 
of 16 misclassified patients, which would be 11 for 18F-FET. 11C-MET would induce the lowest number of 
misclassifications, with 10 out of the 100 patients being misclassified. 
 
DISCUSSION 
This systematic review and meta-analysis, including 39 studies, is the first to pool the results of all 
PET tracers for distinguishing tumor progression from treatment-related changes in high-grade glioma 
patients. This meta-analysis shows that PET can reliably differentiate tumor progression from treatment-
related changes, with the highest diagnostic accuracy being reached among amino-acid tracers.  
A substantial variety of PET tracers has been empirically studied for this purpose, including 
(among others) tracers that demonstrate glucose metabolism (18F-FDG) or amino acid uptake (11C-MET, 
18F-FET, 18F-FDOPA), or are markers of cell proliferation (18F-FLT) or membrane phospholipids (18F-
FCH, 11C-CHO). It is demonstrated that 18F-FET and 11C-MET showed a higher sensitivity than 18F-FDG 
in the differentiation between treatment-related changes and true progression.  
18F-FDG is currently the most commonly used PET-tracer in oncology (9), and therefore the most 
readily available. However, 18F-FDG PET showed the lowest accuracy of all repeatedly-studied tracers, 
which is due to its relatively low sensitivity of 84%; this can be explained by the high physiological 
uptake of glucose in the brain, making it more difficult to detect true tumor progression when a glucose-
based tracer is used (9). 
11C-MET and 18F-FET are, when available, preferred over 18F-FDG due to their higher sensitivity. 
Combining all the gathered evidence, there does not seem to be one particular PET tracer that should be 
recommended over other tracers. Although 11C-MET showed the highest sensitivity for tumor progression 
in the pooled analysis, its availability is limited to hospitals with an on-site cyclotron due to its short half-
life of approximately 20 min (9). When it is not available, 18F-FET is a good alternative with similar 
diagnostic accuracy. Compared to 11C, 18F-based tracers (with a half-life of approximately 110 min) have 
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the logistical advantage of not requiring the on-site cyclotron and allow the usage of the existing 18F-FDG-
based infrastructure for their deliverance, thus facilitating their availability.  
18F-FLT and 18F-FDOPA, as well as some other less common tracers, have shown promising 
results in a small amount of studies and could be comparable or competitive to 18F-FET and 11C-MET in 
terms of diagnostic accuracy. However, these tracers need to be studied more.   
Previously, a systematic review and meta-analysis has been performed for a similar patient 
population, in which different advanced MRI techniques are compared (54). When comparing these PET 
results to those MRI results, it is apparent that magnetic resonance spectroscopy (MRS; the advanced MRI 
technique with the best results) seems to have a higher specificity (95%) than 11C-MET and 18F-FET PET. 
However, their sensitivities are comparable and diagnostic accuracies of these amino-acid PET tracers are 
at least similar to those of all other studied MRI techniques, including perfusion and diffusion MRI. 
Recently it was demonstrated that 18F-FET PET outperforms diffusion MRI in differentiating treatment-
related changes from tumor progression (55). An additional consideration is that the advanced MRI 
methods suffer from limitations such as challenging interpretation and frequent impairment by 
susceptibility artifacts; in contrast, amino-acid PET scan reading is relatively easy due to high tumor-to-
background contrast (9). Further limitations of advanced MRI techniques are the lack of standardization of 
acquisition protocols and post-processing methods, and the large variety of thresholds of quantitative 
parameters (54,56). Disadvantages of amino-acid PET relative to MRI include the necessity of additional 
scanning, its smaller availability, lower spatial resolution and higher expenses (9). Combining PET and 
MRI on hybrid devices might be able to circumvent some of the downsides of each individual imaging 
modality (57) and is more convenient for patients than separate investigations, but these systems are 
inherently costly. 
Several limitations can be noted regarding this review. First, publication bias might have 
influenced the diagnostic accuracy of many of the tracers included in this review. This holds not only for 
tracers that were used in only a limited amount of studies, but publication bias might also have played a 
role for 18F-FDG; its diagnostic accuracy is higher than we expected based on the apparent consensus that 
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this tracer is only of moderate additional value to MRI for differentiating true tumor progression and 
treatment-related changes in gliomas due to beforementioned higher background uptake (1). 
Second, the review included nine abstracts (24–26,31,33,36,37,42,47). Although inclusion of 
abstracts (partially) prevents publication bias, quality and extend of information provided in abstracts is 
limited and they have not usually undergone the same peer review process as full articles.  
Third, a substantial variation exists between the included studies in terms of reference standard 
(Supplementary Table 4). The vast majority of patients for which the reference standard is described, has 
undergone some form of histological or radiological confirmation of the diagnosis. The reliability of 
histological and radiological confirmation may, however, not be equivalent. Furthermore, the reliability of 
the reference standard may differ between the included studies depending on the follow-up duration. 
Although pseudoprogression is most prevalent within the first 12 weeks after completion of the concurrent 
chemoradiotherapy (CCRT), it has been suggested that around one third of the cases occurs after more 
than three months post-CCRT (3,58). However, no difference could be seen between early follow-up 
studies and studies that were conducted more than three months after CCRT.  
Fourth, the method to judge PET positivity showed a large variation between the included studies 
(Supplementary Table 4). Many studies used a visual analysis, which is often unstandardized and may 
lead to clinician-dependent results. Moreover, semi-quantitative cut-offs were often based on a ROC-
analysis that was itself partially based on patients that were not included in this review (e.g. low-grade 
glioma patients). In theory, the accuracy of all tracers would be better than reported here when the cut-offs 
would be optimized for the population of this review. Also, the different cut-offs in the semi-quantitative 
analyses might have led to artificial differences in the trade-off between sensitivity and specificity 
between studies and tracers. A well-justified recommendation regarding the optimal cut-off values for the 
different PET tracers in order to most precisely differentiate post-therapeutic changes from tumor 
progression is currently hindered by the high variability of the used cutoffs, even though it would be a 
valuable guideline for the clinician in daily practice. However, attempts are now being made to provide 
evidence-based recommendations for clinical use of PET imaging in glioma patients (59). 
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Fifth, the comparisons between different PET tracers in this review lack statistical support, as this 
meta-analysis contains largely non-comparative studies of the different PET tracers. Only two studies 
compared 18F-FDG and 11C-MET in the same patient population (21,46). We did not directly compare the 
PET tracers, because the differences in study design, patient groups and reference standard can confound 
the differences in diagnostic accuracy (60). 
Finally, isocitrate dehydrogenase (IDH) mutation status of patients was not provided for most 
included studies. The occurrence of treatment-induced changes in relation to IDH mutation status should 
therefore be studied further.  
In order to overcome some of the above-mentioned limitations, more large prospective studies are 
needed, especially on other PET tracers than 18F-FDG, ideally testing more than one tracer in the same 
population such that results can be directly compared. These studies should use cut-off values that are 
predefined and are based on earlier studies (such as those included in this review) that study the same 
patient population. However, different post-processing protocols may have considerable influence on 





This meta-analysis demonstrated a clear advantage of 11C-MET and 18F-FET over 18F-FDG for 
differentiation between true progression and treatment-induced changes in patients with high-grade 
glioma, with 11C-MET and 18F-FET having the highest sensitivity and specificity, respectively. Diagnostic 
accuracy does not differ substantially between 11C-MET and 18F-FET. Hence, this meta-analysis supports 
the recommendations of the RANO group of implementing amino-acid PET in the treatment response 
evaluation of patients with high-grade glioma. A number of other PET tracers show promising results but 
have so far been insufficiently studied to warrant a direct comparison. Implication of the here-mentioned 
recommendations into clinical practice would be an important step in accurately differentiating true 
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progression from treatment-related changes in high-grade glioma patients presenting with possible 
progression after treatment, and is therefore highly relevant for making well-justified treatment decisions 




University of Groningen (Mandema stipendium to A.H., Junior Scientific Masterclass grant to B.D.). No 




QUESTION: Which PET tracer can be best used to differentiate tumor progression from treatment 
changes in high-grade gliomas? 
PERTINENT FINDINGS: This meta-analysis shows that 18F-FET and 11C-MET, both amino-acid tracers, 
showed a comparable higher sensitivity than 18F-FDG in the differentiation between tumor progression 
and treatment-related changes in high-grade glioma patients. 
IMPLICATIONS FOR PATIENT CARE: Amino PET should be implemented in treatment follow-up of 
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Figure 1: Flow chart of included studies 
 
Abbreviations: PET = positron emission tomography. See Supplementary Table 3  
for tracer abbreviations.  
  




Table 1: Forest plots with 2x2 tables, sensitivity and specificity per study
 
Abbreviations: CI = confidence interval; FN = false negatives; FP = false positives; TN = true negatives; 
TP = true positives. See Supplementary Table 3 for tracer abbreviations.
by University of Groningen on September 23, 2019. For personal use only. jnm.snmjournals.org Downloaded from 
25 
 
Table 2: Pooled analyses of PET tracers. 








18F-FDG 12 171 84 (72-92) 84 (69-93) 5.29 (2.45-11.39) 0.19 (0.10-0.36) 
18F-FET 7 172 90 (81-95) 85 (71-93) 5.80 (2.89-11.66) 0.12 (0.06-0.24) 
11C-MET 8 151 93 (80-98) 82 (68-91) 5.12 (2.71-9.69) 0.09 (0.03-0.26) 
18F-FDG (SA) 6 121 82 (64-92) 79 (61-90) 3.95 (1.90-8.21) 0.23 (0.10-0.51) 
18F-FET (SA) 6 164 90 (80-96) 86 (72-94) 6.56 (3.02-14.21) 0.11 (0.05-0.24) 
11C-MET (SA) 6 135 91 (78-97) 83 (68-92) 5.32 (2.68-10.55) 0.11 (0.04-0.28) 
Abbreviations: CI = confidence interval; LR = likelihood ratio; N = number of PET scans; SA = sensitivity 
analysis without small studies. See Supplementary Table 3 for tracer abbreviations. 
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All searches were performed on 2018-03-29. 
Pubmed: 
("Glioma"[Mesh] OR glioma*[tiab] OR glioblastom*[tiab] OR astrocytom*[tiab] OR 
oligodendrogliom*[tiab] OR oligoastrocytom*[tiab] OR (glia*[tiab] AND (tumor[tiab] OR 
tumour[tiab]))) AND ("Positron-Emission Tomography"[Mesh] OR PET[tiab] OR Positron 
emission[tiab]) AND ("Disease Progression"[Mesh] OR "Treatment Outcome"[Mesh:NoExp] OR 
"Radiation Injuries"[Mesh] OR "Dose-Response Relationship, Radiation"[Mesh] OR "radiation 
effects" [Subheading] OR treatment-induc*[tiab] OR radiation induc*[tiab] OR radiation 
associat*[tiab] OR radiation chang*[tiab] OR radiation effect*[tiab] OR treatment effect*[tiab] OR 
post treat*[tiab] OR posttreat*[tiab] OR posttherap*[tiab] OR post therap*[tiab] OR postsurg*[tiab] 
OR post-surg*[tiab] OR post irradiat*[tiab] OR postirradiat*[tiab] OR after irradia*[tiab] OR after 
rad*[tiab] OR post radiat*[tiab] OR postradiat*[tiab] OR treatment outcome*[tiab] OR radiation 
injur*[tiab] OR pseudo progress*[tiab] OR true progress*[tiab] OR pseudoprogress*[tiab] OR 
pseudorespon*[tiab] OR radiation necro*[tiab] OR radio necro*[tiab] OR radionecros*[tiab] OR 
disease progress*[tiab] OR recurrent glio*[tiab] OR true tumo*[tiab] OR treatment-relat*[tiab] OR 
residu*[tiab] OR pseudo[tiab] OR ((recurr*[tiab] OR progress*[tiab]) AND (tumor*[tiab] OR 
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Web of Science: 
You searched for: TS=(glioma* OR glioblastom* OR astrocytom* OR oligodendrogliom* OR 
oligoastrocytom* OR (glia* AND (tumor OR tumour))) AND TS=(PET OR “Positron emission”) 
AND (TS=(necro* OR radionecro* OR true OR residu* OR pseudo* OR posttreat* OR 
posttherap* OR postsurg* OR postirradi* OR postradiat*) OR TS=(treatment NEAR/2 (induc* OR 
effect OR effects OR relat* OR outcome* OR post)) OR TS=(radiation NEAR/2 (induc* OR 
associat* OR chang* OR effect* OR injur*)) OR TS=((post OR after) NEAR/1 (treat* OR surg* 
OR therap* OR irradiat* OR radiat*)) OR TS=(true NEAR/5 progress*) OR TS=(disease NEAR/1 
(course OR progress*)) OR TS=(recurr* NEAR/5 glio*) OR TS=((recurr* OR progress*) AND 
(tumor* OR tumour*)))  
Refined by: PUBLICATION YEARS: ( 2014 OR 2010 OR 2018 OR 2017 OR 2008 OR 2015 
OR 2007 OR 2013 OR 2006 OR 2016 OR 2012 OR 2005 OR 2009 OR 2011 )  
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, A&HCI, ESCI.  
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Embase: 
(('glioma'/exp OR 'glioma' OR glioma*:ab,ti OR glioblastom*:ab,ti OR astrocytom*:ab,ti OR 
oligodendrogliom*:ab,ti OR oligoastrocytom*:ab,ti OR (glia*:ab,ti AND (tumor:ab,ti OR 
tumour:ab,ti))) AND ('positron emission tomography'/exp OR 'positron emission tomography' OR 
pet:ab,ti OR 'positron emission':ab,ti) AND ('disease exacerbation'/exp OR 'disease 
exacerbation' OR 'disease course'/exp OR 'disease course' OR 'treatment outcome'/exp OR 
'treatment outcome' OR 'clinical outcome'/exp OR 'clinical outcome' OR 'radiation injury'/exp OR 
'radiation injury' OR 'radiation response'/exp OR 'radiation response' OR 'minimal residual 
disease'/exp OR 'minimal residual disease' OR ((treatment NEAR/2 (induc* OR effect OR effects 
OR relat* OR outcome* OR post)):ab,ti) OR ((radiation NEXT/2 (induc* OR associat* OR chang* 
OR effect* OR injur*)):ab,ti) OR (((post OR after) NEXT/1 (treat* OR surg* OR therap* OR 
irradiat* OR radiat*)):ab,ti) OR posttreat*:ab,ti OR posttherap*:ab,ti OR postsurg*:ab,ti OR 
postirradiat*:ab,ti OR postradiat*:ab,ti OR ((true NEAR/5 progress*):ab,ti) OR radionecros*:ab,ti 
OR ((disease NEXT/1 (course OR progress*)):ab,ti) OR ((recurr* NEAR/5 glio*):ab,ti) OR 
residu*:ab,ti OR pseudo*:ab,ti OR necro*:ab,ti OR ((recurr*:ab,ti OR progress*:ab,ti) AND 
(tumor*:ab,ti OR tumour*:ab,ti)))) AND (2005:py OR 2006:py OR 2007:py OR 2008:py OR 
2009:py OR 2010:py OR 2011:py OR 2012:py OR 2013:py OR 2014:py OR 2015:py OR 
2016:py OR 2017:py OR 2018:py) 
 
Results: 2,518 
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Methodological Quality of Included Studies 
In the first domain regarding patient selection, one out of 39 studies (3%) was considered to be of high 
risk of bias (19), since patients who demonstrated significant tumor growth were excluded from the 
analysis. This might have induced a selection bias. Furthermore, 17 studies (44%) were considered to be 
of unclear risk of bias since it was not specified whether their patient selection was random or consecutive 
(18,21,24–26,31–33,37–39,41–43,46,47,51). The remaining 21 studies (54%) were considered to be of 
low risk of bias (7,16,17,20,22,23,27–30,34–36,40,44,45,48–50,52,53).  
In the index test domain 20 studies (51%) were considered to be of high risk of bias, 19 of which 
because they did not pre-specify the PET threshold or cut-off value (7,17,18,21,22,28–32,35,38–
43,46,51), and one study due to awareness of the evaluating physician of the results of the reference test 
(16). In an additional 9 studies (23%) it was not assured that the results of the reviewed PET technique 
were interpreted without knowledge of the results of the reference standard (23,25,26,33,36,47–49,53). 
Hence, we considered them to be of unclear risk of bias. We considered the 10 remaining studies (26%) to 
be of low risk of bias (19,20,24,27,34,37,44,45,50,52). 
In the domain of the reference standard, four studies (10%) were considered to be of high risk; one 
of these studies used a too high pathologic cut-off for tumor progression (20% viable tumor in the 
pathologic specimen) (51), whereas in the other three studies the reference standard results were 
interpreted without blinding to the PET results (7,30,49). All 35 other studies (90%) were considered to be 
of unclear risk of bias as it was not specified if the reference standard results were interpreted without 
knowledge of the PET results (16–29,31–48,50,52,53). Moreover, in four of these studies, the reference 
standard itself was too imprecisely described (16,24,28,33). 
Finally, in the flow and timing domain, 30 studies (77%) were considered to be of high risk of 
bias, because not all patients received the same reference standard (7,17–23,25–29,31,32,34–38,43–
46,48–51,53) or because not all patients were included in the analysis (30). Five other studies (13%) were 
considered to be of unclear risk of bias, as it was unknown if all patients received the same reference 
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standard (16,24,33) or the interval between the PET and the reference standard was not specified (42,47). 
The remaining four studies (10%) were considered to be of low risk of bias (39–41,52). 
All studies showed high risk of bias in at least one of the four domains with the exception of four 
studies (24,33,47,52). However, none of the studies showed low risk of bias in all domains. Overall, study 
quality can be regarded as moderate. 
Regarding the applicability assessment, we had concerns that the included patients and setting 
matched our review question in one study (3%), as not all high-grade glioma patients received treatment 
according to Stupp (49). In 19 other studies (49%), there were limited patient applicability concerns 
(16,21,22,24–27,31–34,36,37,41,42,44,45,47,50); in 18 of these studies, there were limited concerns if all 
patients were treated according to the Stupp protocol (16,21,25–27,31–34,36,41,42,44,45,47,50) and/or if 
there were no patients <18 years included (24–26,31,34,37,45,47,50). In one study, it was not explicitly 
stated that all patients were high-grade glioma patients (22). In the 19 remaining studies, there were no 
concerns regarding patient applicability (7,17–20,23,28–30,35,38–40,43,46,48,51–53). In two studies 
(5%), there were applicability concerns regarding the PET conduct and interpretation (39,42) that might 
not be feasible in clinical practice. In one study, a relatively complicated cluster analysis was performed 
(39). In the other study, a modified 11C-MET PET was used (exclusion of vascular factors from a normal 
11C-MET PET) (42). There were no concerns in any of the other studies regarding applicability of index 
test. Moreover, there were no concerns that the reference standard did not match our review question in 
any of the studies. In conclusion, we had no applicability concern for 18 out of the 39 included studies 
(7,17–20,23,28–30,35,38,40,43,46,48,51–53). 
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PRISMA 2009 Checklist 
Section/topic  # Checklist item  
Reported on page # 
(page numbers refer to 
the original manuscript, 
which may differ from 
those in the published 
article) 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
5 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated.  
Supplementary material 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made.  
6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in any 
data synthesis.  
6 
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PRISMA 2009 Checklist 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6-7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
6-7 
 
Page 1 of 2  
Section/topic  # Checklist item  Reported on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).  
Not possible to specify, as no 
formal assessment was 
performed. A reflection on the 
possibility of publication bias 
is provided in the discussion 
on page 14. 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified.  
6-7 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons 
for exclusions at each stage, ideally with a flow diagram.  
8 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
Supplementary table 3 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see 
item 12).  
8-10, and table 3 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
As this is a review of 
diagnostic studies, there is no 
intervention. Equivalent 
information (i.e. 2x2-tables) is 
presented in table 2 and 
forest plots are shown in table 
4. 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
10-12, and table 5 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  See discussion on page 14 
for a reflection regarding 
publication bias. 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]).  
10-12, and table 5 
DISCUSSION   
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PRISMA 2009 Checklist 
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
13-16 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
14-15 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for 
future research.  
15-16 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role 
of funders for the systematic review.  
17 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Supplementary Table 3: PET tracers, their abbreviations and their (suggested) working mechanism. 
Abbreviation Full name or explanation Indicator of 
18F-FDG 2-18F-fluoro-2-deoxy-D-glucose Glucose metabolism 
18F-FET O-(2-18F-fluoroethyl)-L-tyrosine Amino acid uptake 
18F-FLT 3′-deoxy-3′-18F-fluorothymidine Cell proliferation 
18F-FDOPA 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine Amino acid uptake 
18F-FCH 18F-fluorocholine Membrane phospholipid 
11C-MET (S-11C-methyl)-L-methionine Amino acid uptake 
11C-CHO 11C-choline Membrane phospholipid 
11C-AMT α-11C-methyl-L-tryptophan Amino acid uptake 
13N-NH3 13N-ammonia Perfusion 
18F-FPPRGD2 18F-FPPRGD2 (FDA eIND 104150) Angiogenesis 
mod-MET 11C-MET without vascular factors Amino acid uptake 
Abbreviations: eIND = exploratory investigative new drug; FDA = Food and Drug Administration; mod = 
modified. 
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Method of analysis TP FP TN FN 
Alkonyi et al. 
(18) 





Unknown HGG with potential tumor 
recurrence or radiation 










Lesion-to-cortex K-ratio > 
1.5-1.7 
4 0 6 0 
Arora et al. 
(27) 






Pros HGG with 
clinical/radiological 









60 min; CT 
Visual inspection 11 1 3 3 
D’Souza et al. 
(20) 





Unknown HGG patients who 











L/N tissue ratio > 1.58 16 2 8 1 










Retro HGG with new or 
progressive enhancement 
on MRI after treatment 
Histology (N 
= 12), 
imaging (N = 
18), clinical 





Relative SUVpeak > 2.26 13 2 6 11 
Enslow et al. 
(41) 
10 60.0* (22-75)* WHO IV: 
10 
Unknown GBM patients who 
underwent PET for 
differentiating between 
radiation necrosis and 
recurrent tumor for a new 
enhancing lesion on Gd-
MRI, after treatment 




45-75 min;  
Visual inspection 6 1 2 1 
         
Ratio Lesion-White Matter 
> 1.83 
6 0 3 1 
         
SUVmax ≥ 6.20 6 0 3 1 
        
18F-FLT; 370 





Visual inspection 6 1 2 1 
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Kimax ≥ 0.0165 7 0 3 0 
         
SUVmax ≥1.34 6 0 3 1 
Galldiks et al. 
(28) 




Retro GBM with new lesions or 
an enlargement of 
constrast-enhancing 
lesions on standard MRI 
(gadolinium-based contrast 
agent) within the first 12 w 












200 MBq; up 
to 50 min 
(dynamic);  
TBRmax > 2.3 11 1 10 0 
         TBRmean > 2.0 9 2 9 2 
 21   WHO IV: 
21 
    TBRmax > 2.3 and kinetic 
pattern II or III 
8 1 10 2 
         
TBRmean > 2.0 and kinetic 
pattern II or III 
6 1 10 4 
Garcia et al. 
(38) 
30 53.3 55 ± 13 WHO III + 
IV: 30 
Retro HGG with indeterminate 





(N = 27) 
11C-MET; 6 
MBq/kg; 20-
30 min; CT 
Visual inspection 21 2 7 0 
         
Lesion/background SUV 
ratio > 2.35 
19 0 9 2 
Herrmann et 110 65.5 51.7 ± WHO IV: Retro GBM with suspected Histology (N 18F-FDOPA; Visual inspection 69 8 21 12 
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al. (32) 12.1 (23-
80) 
110 glioblastoma recurrence 
based on contrast 









         
max L/S ≥ 1.0 68 11 18 13 
Hiob et al. 
(31) 
45 (60) Unknown Unknown WHO III + 
WHO IV: 
60⁰ 
Unknown HGG with contrast-
enhancing lesion(s) 
suggestive of recurrence 











Exact decision rule not 
provided, using both 
static and dynamic 
imaging 
39 2 13 6 
         
Using exclusively static 
imaging 
37 2 13 8 
Hojjati et al. 
(51) 




Retro GBM with new and/or 
increasing enhancement 












Relative mean ≥ 1.47 15 1 4 3 
         
Relative median ≥ 1.48  15 1 4 3 
         
Relative max ≥ 1.86  14 1 4 4 
        
57-67 min; 
MRI 
Relative mean ≥ 1.31 18 1 4 0 
         
Relative median ≥ 1.35 17 1 4 1 
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Relative max ≥ 1.90 15 0 5 3 
Hong et al. 
(53) 





Unknown HGG with suspected 









Visual inspection 5 2 0 0 
         
T/N ratio  > 1.18 5 2 0 0 
        
18F-FDG; 
370 MBq; 
65-80 min;  
Visual inspection 4 1 1 1 
Hu et al. (26) 16 Unknown Unknown WHO III + 
WHO IV: 
16 
Unknown HGG patients who 










Visual inspection 6 3 7 0 
Iagaru et al. 
(33) 





Unknown GBM patients with 
suspected recurrence 












Unknown 5 0 3 0 




Unknown 3 0 3 2 
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CT 
Imani et al. 
(19) 




Retro HGG with MRI and clinical 
symptoms suggestive but 
not conclusive of 
progression after treatment 
Radioclinical 





Visual inspection 2 0 4 0 
Iravani et al. 
(36) 
6 Unknown Unknown WHO III + 
WHO IV: 
6 
Retro HGG patients referred for 
FET-PET with suspected 









TBRmax > 2.5 6 0 0 0 
Jena et al. 
(22) 






Pros Glioma patients with high 
index of suspicion of 
recurrence clinically and/or 
in the follow-up contrast-





(N = 19)⁰ 
18F-FET; 
222 ± 30 
MBq; 0-25 
min; MRI 
TBRmax > 2.11 25 2 4 0 
         
TBRmean ≥ 1.437 24 4 2 1 
Jeong et al. 
(35) 





Retro HGG with abnormal 
enhanced lesion on follow-








SUVmax > 0.8 9 0 2 0 
 





    
LNR > 3.00 9 0 1 0 
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SUVmax > 1.66 8 0 2 1 
 





    
LNR > 2.46 7 0 1 2 
Karunanithi et 
al. (45) 





Pros HGG with clinical suspicion 











Visual inspection 18 0 6 0 
Karunanithi et 
al. (50) 





Pros HGG with  clinical/imaging 











10 min*; CT 
Visual 10 0 5 3 
Kebir et al. 
(40) 




Retro GBM patients experiencing 
increasing contrast-
enhancing lesions on MRI 
after treatment 
Imaging (N = 
16) 
18F-FET; 
200 MBq; up 
to 50 min 
(dynamic);  
TBRmax > 1.9 11 0 3 2 
         
TBRmean > 1.9 10 0 3 3 
Kebir et al. 8 50.0 55.4 (29- WHO III: 
2; WHO 
Retro HGG with increasing 
constrast-enhancing 
Imaging (N = 18F-FET; 
200 MBq; 
Cluster (based mainly on 5 1 1 1 
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(39) 70) IV: 6 lesions on MRI and/or any 
new lesion more than 4 w 
after end of treatment 
8) 20-40 min; 
CT 
textural PET features) < 3 
Khangembam 
et al. (34) 






Pros HGG with clinical suspicion 










Visual inspection 7 3 6 2 







Visual inspection 7 3 6 2 





Retro HGG patients who received 
MET PET to differentiate 
between tumor recurrence 








SURmaxmirror > 1.62 5 1 1 0 
Lapa et al. 
(52) 





Pros HGG with suspected 




175 ± 39 
MBq*; 15-35 
min; CT 
Visual inspection 23 0 0 0 
        
18F-FET; 
217 ± 13 
Visual inspection 23 0 0 0 
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MBq*; 10-20 
min; CT 
Li et al. (23) 12 66.7 48.2 WHO III: 
4; WHO 
IV: 8 
Unknown HGG with suspicion of 






(N = 9) 
11C-choline; 
370 MBq; 5-
9 min; CT 
Visual inspection 4 2 6 0 
         
T/N > 1.42 4 1 7 0 
Martínez-
Amador et al. 
(48) 





Retro HGG with MRI suspicion of 










Visual inspection 10 0 0 3 
         
L/CP SUVmax ≥ 1.21 9 0 0 4 
Montes et al. 
(44) 





Pros HGG with clinical and/or 
radiological suspicion of 





(N = 8) 
18F-FCH; 
370 MBq; 
start after 50 
min 
Visual inspection 9 0 2 0 
Nakajima et 
al. (43) 





Retro HGG patients who 
developed recurrent 
lesions on MRI suspected 
to be recurrent tumor or 









30 min;  
L/R > 2.00 4 0 9 1 
Paquet et al. 35 (60) Unknown 60 WHO III: Pros HGG patients who Histology (N 18F-FDOPA; Visual 47 3 8 2 
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(37) 1; WHO 
IV: 34 
underwent PET after 
treatment 
= 15), 




100 min; CT 
Park et al. (7) 31 48.4 50.3 WHO III: 
4; WHO 
IV: 27 
Retro HGG with clinical indication 










TNRmax > 1.40 21 2 3 5 
Pyka et al. 
(47) 
6 54.2* 52* WHO III + 
WHO IV: 
6 
Unknown HGG patients who had 








Unknown 4 0 0 2 
Sharma et al. 
(46) 





Retro HGG patients investigated 
with PET for detection of 
recurrent disease after 
treatment 
Clinical (N = 
9), imaging 





Visual inspection 10 0 2 0 
         
TBR ≥ 1.47 10 0 2 0 
        
18F-FDG; 
370 MBq; 
start after 60 
min, 15-20 
min per bed 
position; CT 
Visual inspection 9 0 2 1 
Sher et al. 10 Unknown Unknown WHO III + 
WHO IV: 
Unknown HGG with MR evidence of 
progressive disease per 
Unknown 18F-FDG; 
unknown; 
Visual inspection 7 0 1 2 
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 9 0 1 0 






 9 0 1 0 
Shishido et 
al. (29) 






Retro HGG patients with first 
radiological suspicion of 





(N = 8) 
11C-MET; 
215 ± 58 
MBq (126-
318 MBq); 
10-15 min;  
L/N ratio ≥2.69 12 1 5 3 
         
Visual inspection 15 5 1 0 
        
18F-FLT; 204 
± 79 MBq 
(91-337 
MBq); 40-50 
L/N ratio ≥4.94 14 2 4 1 
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min; 
         
Visual inspection 15 6 0 0 
Takenaka et 
al. (42) 
49 Unknown Unknown WHO III: 
16; WHO 
IV: 17‡ 
Unknown Unknown, but results 
suggest that exclusively 
HGG patients for which a 
differentiation between 
tumor reccurence and 
radiation necrosis was 










L/N ratio > 4.75 26 1 15 7 
Testart et al. 
(25) 
9 43* 46.9 ± 
6.2* 
Unknown Pros HGG under suspicion of 









Unknown 9 0 0 0 
Tripathi et al. 
(21) 





Pros HGG patients evaluated for 










40 min; CT 
T/N ratio >1.9  8 0 1 0 




80 min; CT 
T/N ratio >0.75 7 0 1 1 
Verger et al. 23 (24) 50⁰ 51.8 (29- WHO III: 
2; WHO 
Retro HGG with standard MRI 





Visual inspection 14 3 3 4 
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to 50 min 
(dynamic); 
MRI 
         
TBRmax >2.61 14 1 5 4 
Yamamoto et 
al. (16) 




Retro GBM with signs of tumor 
recurrence based on 
clinical and/or radiologic 






5-60 min;  
Visual inspection 10 0 0 0 
† Note that this is the number of patients/tumors that is included in this review. In general, this is not necessarily the same as the number of patients/tumors in the referred article. 
‡ Histology not provided for primary diagnoses but for recurrences. Thus, the 16 patients without tumor progression are not taken into account in these numbers. 
* = based on a larger patient group 
⁰ = based on number of tumours, not on number of patients 
Abbreviations: Bq = becquerel; CT = computed tomography; FN = false negatives; FP = false positives; GBM = glioblastoma multiforme; Gd = Gadolinium; HGG = high-grade glioma; 
kg = kilogram; Kimax = Patlak-derived metabolic flux parameter;  L/CP = lesion/contralateral parenchyma; L/N = lesion-to-normal ratio; L/S = lesion-to-striatum ratio; LNR = lesion-to-
normal ratio; max = maximal; min = minute; mo = months; mod = modified; MR = magnetic resonance; MRI = magnetic resonance imaging; PET = positron emission tomography; Pros 
= prospective; RANO = Response assessment in neuro-oncology; Retro = retrospective; SD = standard deviation; SUR = lesion-to-background SUV ratio; SUV = standard uptake 
value; T/N = tumor-to-normal ratio; TBR = tumor-to-background ratio; TN = true negatives; TNR = tumor-to-normal ratio; TP = true positives; w = weeks; WHO = World Health 
Organization. See Supplementary Table 3 for a list of PET tracer abbreviations. 
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Supplementary Table 5: General characteristics of included patients, lesions and scans. 
Patients (number)  771* 
Lesions (number)  832 
Scans (number)  951 
 18F-FDG 171 
 18F-FET 207 
 11C-MET 164 
 18F-FLT 54 
 18F-FDOPA 192 
 11C-CHO 24 
 18F-FCH 20 
 13N-NH3 18 
 mod-MET 49 
 11C-AMT 10 
 18F-FPPRGD2 8 
Mean age (years)  50.2† 
% Male  65.0‡ 
Histology (number) WHO III 145 
 WHO IV 478 
 WHO III or IV (not specified) 209 
Follow-up (number) Histology 257 
 Imaging 120 
 Clinical 11 
 Combination or unknown on the 
individual lesion level 
444 
% True progression  73.4§ 
* For one study (48), only a number of 13 PET scans is known. For this study, the number of 
patients is assumed to be the same as the number of scans. † Calculated using studies for 
which mean age is known only. ‡ Calculated using studies for which the percentage of males is 
known only. § Based on the number of lesions 
Abbreviations: WHO = World Health Organization. See Supplementary Table 3 for a list of PET 
tracer abbreviations. 
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Supplementary Table 6: Quality assessment of included studies. 










































Alkonyi et al. (18) ? - ? -  + + + 
Arora et al. (27) + + ? -  ? + + 
D'Souza et al. (20) + + ? -  + + + 
Dankbaar et al. (17) + - ? -  + + + 
Enslow et al. (41) ? - ? +  ? + + 
Galldiks et al. (28) + - ? -  + + + 
Garcia et al. (38) ? - ? -  + + + 
Herrmann et al. (32) ? - ? -  ? + + 
Hiob et al. (31) ? - ? -  ? + + 
Hojjati et al. (51) ? - - -  + + + 
Hong et al. (53) + ? ? -  + + + 
Hu et al. (26) ? ? ? -  ? + + 
Iagaru et al. (33) ? ? ? ?  ? + + 
Imani et al. (19) - + ? -  + + + 
Iravani et al. (36) + ? ? -  ? + + 
Jena et al. (22) + - ? -  ? + + 
Jeong et al. (35) + - ? -  + + + 
Karunanithi et al. (45) + + ? -  ? + + 
Karunanithi et al. (50) + + ? -  ? + + 
Kebir et al. (40) + - ? +  + + + 
Kebir et al. (39) ? - ? +  + - + 
Khangembam et al. (34) + + ? -  ? + + 
Kits et al. (30) + - - -  + + + 
Lapa et al. (52) + + ? +  + + + 
Li et al. (23) + ? ? -  + + + 
Martínez-Amador et al. (48) + ? ? -  + + + 
Montes et al. (44) + + ? -  ? + + 
Nakajima et al. (43) ? - ? -  + + + 
Paquet et al. (37) ? + ? -  ? + + 
Park et al. (7) + - - -  + + + 
Pyka et al. (47) ? ? ? ?  ? + + 
Sharma et al. (46) ? - ? -  + + + 
Sher et al. (24) ? + ? ?  ? + + 
Shishido et al. (29) + - ? -  + + + 
Takenaka et al. (42) ? - ? ?  ? - + 
Testart et al. (25) ? ? ? -  ? + + 
Tripathi et al. (21) ? - ? -  ? + + 
Verger et al. (49) + ? - -  - + + 
Yamamoto et al. (16) + - ? ?  ? + + 
The risk of bias in four different domains and concerns about applicability are shown for the included studies. 
High risk/concern (-), unclear risk/concern (?) and low risk/concern (+). 
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